No Data
No Data
Immunome Doses First Patient in Trial for New Cancer-Fighting Drug IM-1021
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
Express News | Immunome Doses First Patient in Phase 1 Trial of IM-1021, a Ror1-Targeted ADC
Imunon Announces Phase 1 Trial Results For IMNN-101 DNA Vaccine Showing 2-4x Antibody Increase Vs. Omicron Variant With No Serious Adverse Effects In 24 Participants; Vaccine Demonstrated Cross-Reactivity With New Variants
Immunome to Present at Upcoming March Conferences
Aro Biotherapeutics Appoints President And CEO As Board Chair; Appoints Purnanand Sarma As CEO